In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
NASDAQ:INO
Recent Posts
Galexxy Holdings Inc., Appoints High Profile Chief Marketing Officer
RemSleep Holdings Inc. Provides a Corporate Update and Correction
Winners Partner “Horse Races Now” App updated in the Apple App Store and Google Play Store allowing its Users to “Bet Now” with VegasWinners Sportsbook Affiliate Partners
Universal Media Announces AI-Powered Universal Streams Platform
Producción de hidrógeno en América Latina: desafíos, cambios y predicciones
Sign Up To Get Our Instant Alerts!

Popular Post
-
Hollywood Star Cuts Enters Into Acquisition Agreement! 192 views
-
FEED EARTH NOW (FEN) ANNOUNCES FOOD WASTE RECYCLING SYSTEM IN CALIFORNIA 133 views
-
Allied Enters into Gas Offtake Agreement with Sloan Petroleum to Procure Additional Natural Gas Wells for the Enerhash Bitcoin Mining Project 87 views
-
Kimberly Goldwin Poised to Become Next President of ABC News 43 views
-
JPMorgan Bringing Back Employees to Work From Office 41 views